MedPath

Yunu Provides Free Platform Access for Children's Oncology Group Clinical Trials

  • Yunu is extending free use of its clinical trial imaging platform to all Children's Oncology Group (COG) clinical trials nationwide, aiming to improve pediatric cancer care.
  • The initiative waives implementation and platform time-point fees for COG trials at collaborating sites with a Yunu subscription, enhancing access to advanced imaging.
  • Yunu's platform reduces research coordinator time by 80% and radiologist time by 50% on imaging assessments, while also minimizing clinical trial imaging data error rates.
  • This commitment aims to support institutions serving underserved and rare pediatric disease populations, ensuring accurate and timely imaging data for treatment decisions.
Yunu, a provider of clinical trial imaging workflow and data management technology, will extend free use of its platform for all Children’s Oncology Group (COG) clinical trials nationwide. This initiative aims to provide pediatric cancer hospitals access to imaging capabilities by waiving all Yunu implementation and platform time-point fees for COG trials at collaborating sites with a minimal Yunu subscription.

Improving Pediatric Cancer Care

The Children’s Oncology Group (COG), a part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), comprises 10,000 researchers and 200 leading hospitals and cancer centers. COG focuses on conducting clinical trials to improve the prevention, diagnosis, and treatment of cancer in children and adolescents. Over 90% of the 16,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions.

Streamlining Clinical Trials

Yunu's platform currently supports active COG trials, reducing study start-up time for trial teams. The Children’s Oncology Group has nearly 100 active clinical trials open at any given time, including front-line treatment trials, studies on the underlying biology of childhood cancers, and trials involving new treatments, supportive care, and survivorship. All protocols for these trials are readily accessible to users on day one of their platform subscription.

Enhancing Efficiency and Accuracy

Beyond start-up savings, the Yunu platform reduces research coordinator time by 80% and radiologist time by 50% on every trial imaging assessment. Clinical trial imaging data often has error rates of 25-50%, even at leading cancer centers. Yunu aims to transform trial efficiency and accuracy, ensuring audit readiness and reducing these error rates to near zero.

Commitment to Pediatric Cancer

Yunu is dedicated to extending trial imaging excellence to all pediatric cancer hospitals, especially those serving underserved and rare pediatric disease populations. The company’s support of Children’s Oncology Group’s cooperative trials is based on their efforts in pediatric research. Yunu aims to ensure clinicians have accurate, timely, and accessible imaging data to inform treatment and care decisions, improving the chances of survival for children facing cancer.

About Yunu

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu aims to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform daily, Yunu is delivering a new standard for clinical trial imaging workflow.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
Yunu Extends Free Cancer Center Use of Platform for All Children's Oncology Group Clinical Trials
biospace.com · Sep 12, 2024

Yunu extends free use of its clinical trial imaging platform for all Children’s Oncology Group (COG) trials, aiming to e...

© Copyright 2025. All Rights Reserved by MedPath